热带石和神经退行性疾病
Stefan Panaiotov1, Lyubka Tancheva2, Reni Kalfin2,3
1National Centre of Infectious and Parasitic Diseases, Yanko Sakazov Blvd. 26, 1504 Sofia, Bulgaria.
Molecules (Basel, Switzerland)
|June 19, 2024
概括
克林诺皮托利特焦石通过改善肠道健康并表现出排毒作用,对神经退行性疾病 (NDs) 显示出有前途. 这篇评论探讨了它在治疗阿尔茨海默氏症方面的潜力.
科学领域:
- 矿物学和材料科学 矿物学和材料科学
- 神经科学和神经病学 神经科学和神经病学
- 微生物学和肠道健康
背景情况:
- 神经退行性疾病 (NDs),包括阿尔茨海默病 (AD) 和帕金森病 (PD),是与衰老相关的渐进性神经元疾病,患病率越来越高,治疗选择有限.
- 新兴研究强调肠道健康,肠道微生物组和AD和PD的病变发生之间存在强烈的联系,这表明从肠道向大脑的逆行传播.
- 石,特别是克林诺皮托利石,是微孔矿物质,由于其独特的结构特性,具有潜在的治疗应用.
研究的目的:
- 审查clinoptilolite及其活性形式对肠道健康和肠道微生物群的多方面的益处.
- 讨论与ND治疗相关的clinoptilolite的排毒,抗氧化,免疫刺激和抗炎性质.
- 检查clinoptilolite对AD病理学的直接影响及其在PD管理中作为生物传感器和传递系统的潜在用途.
主要方法:
- 对现有关于clinoptilolite,肠道健康和神经退行性疾病的研究进行全面的文献综述.
- 在体外和体内有关克林诺皮托利特对AD病理学影响的数据的分析.
- 探索研究石作为生物传感器和PD的药物输送系统.
主要成果:
- 克林诺皮托莱特对肠道健康和肠道微生物组的调节有显著的积极影响.
- 这种矿物质具有强大的排毒,抗氧化,免疫刺激和抗炎作用.
- 有证据表明,clinoptilolite对AD病理学和PD诊断和治疗中的潜在应用有直接有益的影响.
结论:
- 克林诺皮托利特及其活性形式是治疗神经退行性疾病,特别是AD和PD的有前途的天然治疗剂.
- 它对肠道微生物群的有益作用及其内在的排毒和抗炎性质是其治疗潜力的关键.
- 进一步研究clinoptilolite对神经退行性途径的直接影响及其在先进的传递系统中的应用是有必要的.
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:15Parkinson's Disease: Overview
524
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
524
01:37Neural Regulation
39.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.3K
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179